A Randomised Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)

Project Details

StatusFinished
Effective start/end date1/05/19 → 31/01/23

Funding

  • Avalyn Pharma: A$110,283.00